Physician profile
Gary Slaughter
NPI 1770522328
$54,851.18
in general payments reported to CMS, 2019-2025
35 companies · $3,759 in 2025
The $3,759 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $3,854 · 2021: $10K · 2022: $9,076 · 2023: $9,221 · 2024: $5,397 · 2025: $3,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $3,798 · Travel and Lodging: $297 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,192.64 |
| Consulting Fee | $3,797.91 |
| Travel and Lodging | $296.80 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medimetriks Pharmaceuticals, INC. | $13,514.88 | 2019-2025 | Neo-Synalar, Clindacin Etz, Neuac |
| Epi Health, LLC | $6,787.80 | 2019-2022 | |
| Pfizer INC. | $6,570.91 | 2019-2025 | |
| Incyte Corporation | $5,771.13 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $4,432.32 | 2022-2024 | Vtama |
| Genzyme Corporation | $3,594.46 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,487.31 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $2,024.19 | 2020-2025 | Ilumya |
| Abbvie INC. | $1,338.63 | 2019-2024 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $1,016.49 | 2019-2025 | |
| Amgen INC. | $920.66 | 2019-2025 | Otezla, Otezla, Enbrel |
| Leo Pharma INC. | $718.96 | 2019-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $707.86 | 2019-2024 | Tremfya |
| Galderma Laboratories, L.P. | $698.54 | 2019-2025 | Aklief, Nemluvio |
| Regeneron Healthcare Solutions, INC. | $671.96 | 2019-2025 | Dupixent, Libtayo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $657.49 | 2019-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $559.35 | 2019-2020 | |
| Ucb, INC. | $536.01 | 2021-2025 | Bimzelx |
| Organon LLC | $296.44 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $264.20 | 2019-2021 | |
| Journey Medical Corporation | $255.94 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $251.91 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $142.32 | 2022 | |
| Almirall LLC | $139.59 | 2019-2024 | Klisyri |
| Dermira, INC. | $122.75 | 2019 | |
| Mayne Pharma Commercial LLC | $96.53 | 2022-2023 | |
| Celgene Corporation | $89.19 | 2019 | |
| Sebela Pharmaceuticals INC. | $50.17 | 2019-2022 | |
| Sandoz INC. | $26.53 | 2019 | |
| Ani Pharmaceuticals, INC. | $23.70 | 2023 | Veregen |
| Astrazeneca Pharmaceuticals LP | $22.34 | 2022 | |
| Fresenius Kabi USA, LLC | $19.81 | 2023 | Idacio |
| Botanix Sb INC | $17.45 | 2025 | Sofdra |
| Organogenesis INC. | $15.00 | 2024 | |
| Strata Skin Sciences, INC. | $8.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Slaughter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.